Indivior Pharmaceuticals enters the late-May period with a notable gap opening up between price and short sentiment — the stock has rallied 13% over the past month while shorts are quietly trimming, creating a setup that looks less contested than it did just weeks ago.
Short sellers have been stepping back consistently. SI as a percentage of the free float has dropped from a recent peak above 12.8% in early May to 11.3% now, shedding roughly 1.1 million borrowed shares over the month. The retreat accelerated around the May 8-11 window, when a block of shorts closed out, taking the float percentage down from ~12.4% to ~11.2% in a matter of days. Despite that reduction, the position remains meaningful — over one share in nine is still sold short, which leaves the stock genuinely crowded even on its best recent reading.
The borrow market is not flashing stress. Cost to borrow is just 0.43%, down nearly 10% on the week and 17% over the month — as close to frictionless as a stock with double-digit short interest gets. Availability is extremely loose at over 1,000%, meaning around ten shares are available to borrow for every one currently lent out. That's well within the normal range and far above the tightest level of the past year, which was still a comfortable 571%. Options traders are leaning bullish, or at least indifferent to downside — the put/call ratio is 0.19, well below its 20-day average of 0.35 and the lowest in weeks. There is no meaningful hedging pressure in the options market right now.
The Street remains constructive but in a measured way. The mean analyst price target is $51.50 against a current price of $37, implying roughly 39% upside. The bull case centres on Sublocade's momentum: patient volumes rose 8% year-over-year to around 171,500 in Q3 2025, and the prescriber base expanded 11%. The bear case is harder to ignore, though. Indivior has shrunk its international footprint dramatically — Sublocade's commercial support now covers just four countries, down from roughly forty — and the discontinuation of Opvee removes a secondary growth lever. The consensus sits in neutral territory, reflecting those competing pulls. Valuation looks undemanding: EV/EBITDA is near 7x, down from above 8x a month ago, and PE is running at 9.5x. The EV/EBIT factor ranks in the 74th percentile of the universe, a modest quality signal, while EPS surprise ranks at the 64th percentile.
Institutional positioning shows some divergence worth noting. Vanguard added a substantial 3.97 million shares as of March 31, taking its stake to 4.5% of shares outstanding. Millennium Management added over 2.2 million shares in the same period, bringing its holding to 3.8%. Against that, Madison Avenue Partners trimmed by nearly 2 million shares, and Morgan Stanley cut its position by 852,000 shares. The most recent quarterly snapshot shows buying pressure outpacing selling among the larger names, reinforcing the sense that some institutional money was leaning into the April earnings reaction.
That reaction was strong. The April 30 print sent the stock up 10.3% on the day and 16% over the subsequent five sessions — one of the more decisive single-earnings moves in recent company history. The most recent event on May 13 produced only a modest -1.2% one-day reaction, more likely a data reset than a fresh catalyst. The next scheduled earnings date is July 30, which means the stock has roughly ten weeks before another fundamental test.
With shorts retreating, options traders unbothered, borrow cheap and plentiful, and institutional flows net positive last quarter, the watchlist for INDV heading into summer is centred on one question: whether Sublocade's domestic patient and prescriber growth can compensate for the international pullback when management updates at the July print.
See the live data behind this article on ORTEX.
Open INDV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
